CA
NZ
UK
AU
IND
US
Annexon, Inc. (NASDAQ: ANNX) has announced compelling advancements in its clinical development of tanruprubart, with the FORWARD study demonstrating rapid clinical responses across all treated patients within one week. This positive news comes as the biotechnology firm prepares to submit a Biologics License Application …
Recent reports indicate that AstraZeneca may be pursuing merger discussions with Bristol Myers Squibb. This move represents a potential shift in AstraZeneca's strategic framework, especially considering the company's traditional focus on maintaining a distinct operational model without significant mergers. By engaging in talks with …
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) achieved total revenue of $83.2 million for the quarter ended June 30, 2026, reflecting a 19% increase compared to $70.0 million in the same period last year. Net product sales of LUPKYNIS, the company's FDA-approved therapy for lupus nephritis, …
Despite this disappointing figure, the company's losses were less than analysts had expected, with an earnings per share (EPS) of $-0.83 compared to a consensus estimate of $-1.05. This result indicates a minor improvement in operational efficiency. The stock has seen significant volatility but …
Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported a net loss of $10.6 million for the quarter ending June 30, 2026, marking a significant increase from the $5.5 million net loss recorded in the previous quarter. The earnings per share of $(0.26) exceeded the consensus estimate …
Bausch & Lomb Corporation (NYSE: BLCO) has made significant leadership changes, appointing four new directors to its board effective August 5, 2026. Such changes signal a proactive approach to enhance governance while supporting the company’s objectives in the evolving healthcare sector.
Becton Dickinson and Company (NYSE: BDX) reported a strong revenue figure of $5.0 billion for the fiscal third quarter ending June 30, marking a 5.4% increase compared to the previous year. This figure exceeded analysts' consensus estimates, which anticipated the company would achieve earnings …
Aclaris Therapeutics, Inc. reported an earnings per share (EPS) of $-0.15 for the quarter ended June 30, 2026, which is marginally better than the $-0.16 consensus estimate. This result highlights a slight improvement in performance, contrasting with greater expectations set by market analysts. The …
Agenus Inc. (NASDAQ: AGEN) announced an $85 million capital raise to fund its Phase 3 trial, ROBBIN, targeting neoadjuvant treatment for patients with microsatellite-stable colon cancer. This substantial funding reflects the company’s strategic focus on developing curative approaches for high-risk patients, an underserved market …
Aligos Therapeutics reported a net loss of $1.5 million for Q2 2026, significantly improving from a projected $15.9 million loss. This reduction highlights the company's effective capital management strategies crucial for investor confidence, especially as it moves toward pivotal trial milestones.Key HighlightsThe recently secured …
Please wait processing your request...